+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 19Years +
All Genders
ID07005752

A Phase 4 Study to Test the Safety and Effectiveness of CnU Capsule 750 mg for Treating Cholesterol Gallstones

Led by Myungmoon Pharma. Co. Ltd. · Updated on 2026-07-29

484

Participants Needed

13

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying patients with cholesterol gallstones, specifically those with radiolucent gallstones, to assess the effectiveness and safety of the CnU capsule 750 mg. This phase 4 clinical trial compares this treatment to an active comparator, Ursa tablet, aiming to provide insights into dissolving gallstones and improving patient outcomes. Participants receive either CnU capsule combined with a placebo Ursa tablet or Ursa tablet combined with a placebo CnU capsule. Both treatments are taken orally three times a day after meals for a total duration of 24 weeks. The study includes a randomized, double-blind, parallel design to fairly evaluate and compare these treatments. Throughout the study, participants undergo assessments including abdominal ultrasonography and plain abdominal X-rays to monitor gallstone changes. Researchers measure the response to the dissolution therapy from the start to the end of treatment, focusing on complete and partial dissolution rates. Safety and efficacy are carefully monitored over the 24 weeks, with the total participation lasting until the studys completion in mid-2028.

CONDITIONS

Brief Title

A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones).

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here